Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6053862 | 0.94 | CYP3A4 (0.43) | TTRAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL20659945 | 0.91 | TTR (0.41) | TTRAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL27515109 | 0.90 | TTR (0.40) | TTRAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL9319479 | 0.88 | TTR (0.41) | TTRAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL9319210 | 0.88 | TTR (0.41) | TTRAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL31668182 | 0.88 | TTR (0.41) | TTRAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6248837 | 0.86 | TTR (0.40) | TTRAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7750809 | 0.78 | TTR (0.39) | TTRAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL87887 | 0.76 | HCAR2 (0.43) | TTRAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1122760 | 0.76 | HCAR2 (0.43) | TTRAKR1C4AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021933-B1 | THIOSUCCINYL-CROSSLINKED HEMOGLOBIN ANALOGS AND METHODS OF USE AND PREPARATION THEREOF | BILLION KING INTERNATIONAL LTD (HK) | 2024-10-09 | — | — | EP | disclosed |
| CN-114341174-B | Succinyl cross-linked hemoglobin analogues and methods of use and preparation thereof | 亿京国际有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11891501-B2 | Method of producing resin modifier, resin modifier, and composite material | TOAGOSEI CO., LTD. (JP) | 2024-02-06 | — | — | US | disclosed |
| US-11692022-B2 | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20230111100-A1 | Thiosuccinyl-crosslinked Hemoglobin Analogs and Methods of Use and Preparation Thereof | BILLION KING INTERNATIONAL LIMITED (HK) | 2023-04-13 | — | — | US | disclosed |
| US-11479597-B2 | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2022-10-25 | — | — | US | disclosed |
| EP-4021933-A1 | THIOSUCCINYL-CROSSLINKED HEMOGLOBIN ANALOGS AND METHODS OF USE AND PREPARATION THEREOF | Billion King International Limited (HK) | 2022-07-06 | — | — | EP | disclosed |
| US-20220186015-A1 | METHOD OF PRODUCING RESIN MODIFIER, RESIN MODIFIER, AND COMPOSITE MATERIAL | TOAGOSEI CO., LTD. (JP) | 2022-06-16 | — | — | US | disclosed |
| CN-114341174-A | Thiosuccinyl cross-linked hemoglobin analogs and methods of use and preparation thereof | 亿京国际有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11692022-B2 | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof | HBG1, HBG2, HBB | TTR 7/4885AKR1C4 1573/4885AKR1C3 2099/4885 |
| US-20230111100-A1 | Thiosuccinyl-crosslinked Hemoglobin Analogs and Methods of Use and Preparation Thereof | HBG1, HBG2, HBB | TTR 7/4885AKR1C4 1573/4885AKR1C3 2099/4885 |
| US-11479597-B2 | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof | HBG1, HBG2, HBB | TTR 7/4885AKR1C4 1573/4885AKR1C3 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.